CD30/CD30 Ligand and CD40/CD40 Ligand in Malignant Lymphoid Disorders
Open Access
- 1 July 1999
- journal article
- review article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 14 (3) , 135-143
- https://doi.org/10.1177/172460089901400303
Abstract
CD30 and CD40 are members of the tumor necrosis factor (TNF) receptor family. These two receptors have pleiotropic biologic functions including induction of apoptosis and enhancing cell survival. This review will discuss the pattern of expression of these receptors in malignant lymphoid disorders and their prospective ligands. Understanding issues related to these two ligands and their receptors in lymphoid malignancies may help to improve the classification of these diseases and could open the doors for new treatment strategies.Keywords
This publication has 106 references indexed in Scilit:
- CD30 in Normal and Neoplastic CellsClinical Immunology, 1999
- CD30 ligand is expressed on resting normal and malignant human B lymphocytesBritish Journal of Haematology, 1996
- Human Native Soluble CD40L Is a Biologically Active Trimer, Processed Inside MicrosomesPublished by Elsevier ,1996
- CD30 Ligand, a Member of the TNF Ligand Superfamily, with Growth and Activation Control for CD30+ Lymphoid and Lymphoma Cells*Leukemia & Lymphoma, 1996
- CD30, Th2 cytokines and HIV infections: a complex and fascinating linkImmunology Today, 1995
- A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activationEuropean Journal of Immunology, 1995
- CD40 ligand and its role in X-linked hyper-IgM syndromeImmunology Today, 1993
- Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl‐2 inductionEuropean Journal of Immunology, 1993
- Identification of a source of biologically active CD40 ligandEuropean Journal of Immunology, 1992
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992